Stevanato Group (NYSE:STVN) Raised to Strong-Buy at Wolfe Research

Stevanato Group (NYSE:STVN) was upgraded by research analysts at Wolfe Research to a “strong-buy” rating in a research note issued to investors on Monday,Zacks.com reports.

STVN has been the topic of several other reports. Wall Street Zen downgraded Stevanato Group from a “buy” rating to a “hold” rating in a research report on Saturday, February 14th. Citigroup dropped their price target on Stevanato Group from $32.00 to $26.00 and set a “buy” rating on the stock in a research report on Thursday, March 5th. KeyCorp decreased their price objective on Stevanato Group from $37.00 to $32.00 and set an “overweight” rating on the stock in a report on Thursday, March 5th. Weiss Ratings lowered Stevanato Group from a “hold (c-)” rating to a “sell (d+)” rating in a report on Wednesday, March 11th. Finally, Morgan Stanley decreased their price objective on Stevanato Group from $24.00 to $19.00 and set an “equal weight” rating on the stock in a report on Friday, March 6th. One research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Stevanato Group presently has a consensus rating of “Moderate Buy”.

Stevanato Group Stock Performance

Shares of NYSE STVN opened at €18.92 on Monday. The company has a quick ratio of 1.11, a current ratio of 1.63 and a debt-to-equity ratio of 0.21. The business’s 50 day moving average is €16.08 and its two-hundred day moving average is €17.88. The company has a market cap of $5.73 billion, a P/E ratio of 32.07, a P/E/G ratio of 1.74 and a beta of 0.78. Stevanato Group has a 12 month low of €12.89 and a 12 month high of €28.00.

Stevanato Group (NYSE:STVN) last issued its quarterly earnings results on Friday, May 8th. The company reported €0.11 EPS for the quarter, missing the consensus estimate of €0.12 by (€0.01). The business had revenue of €273.57 million during the quarter. Stevanato Group had a return on equity of 10.27% and a net margin of 11.76%.The firm’s revenue for the quarter was up 6.6% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.10 earnings per share. On average, equities analysts expect that Stevanato Group will post 0.68 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. GW&K Investment Management LLC raised its position in Stevanato Group by 76.2% in the fourth quarter. GW&K Investment Management LLC now owns 2,440 shares of the company’s stock worth $49,000 after purchasing an additional 1,055 shares in the last quarter. Fifth Third Bancorp raised its position in Stevanato Group by 22.6% in the first quarter. Fifth Third Bancorp now owns 4,196 shares of the company’s stock worth $58,000 after purchasing an additional 773 shares in the last quarter. State of Wyoming raised its position in Stevanato Group by 39,216.7% in the second quarter. State of Wyoming now owns 2,359 shares of the company’s stock worth $58,000 after purchasing an additional 2,353 shares in the last quarter. Quantbot Technologies LP acquired a new position in Stevanato Group in the third quarter worth about $68,000. Finally, Van Berkom & Associates Inc. grew its position in Stevanato Group by 50.6% in the third quarter. Van Berkom & Associates Inc. now owns 3,615 shares of the company’s stock valued at $93,000 after acquiring an additional 1,215 shares during the period.

Stevanato Group Company Profile

Stevanato Group is a global provider of primary packaging solutions and related services for the pharmaceutical and biotech industries. The company specializes in the design, development and manufacturing of glass drug containers such as vials, cartridges and pre-fillable syringes, as well as advanced inspection systems and assembly equipment. Its integrated offerings cover the entire packaging supply chain, from component production to bespoke filling lines and serialization technology.

In addition to its core glass business, Stevanato Group delivers engineering services and process validation support to pharmaceutical customers.